Trials / Completed
CompletedNCT02593045
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Innate Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this first in human study is to assess the safety and tolerability of increasing intravenous (IV) doses of single agent IPH4102 administered to patients with relapsed/refractory CTCL to characterize the dose limiting toxicities (DLT) and identify a Maximum Tolerated Dose (MTD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IPH4102 |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2020-04-01
- Completion
- 2020-04-01
- First posted
- 2015-10-30
- Last updated
- 2021-01-20
Locations
5 sites across 4 countries: United States, France, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT02593045. Inclusion in this directory is not an endorsement.